Search Results
10
Everything
Search Filters
Organization
Ensysce Biosciences Inc.
Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 31, 2022 16:05 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to...
Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference
February 23, 2022 08:31 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to...
Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
February 08, 2022 16:01 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to...
Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
January 31, 2022 16:01 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms...
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
January 27, 2022 08:30 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms...
Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting
January 19, 2022 16:19 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that...
Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid
January 10, 2022 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms...
Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference
January 05, 2022 16:05 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that...
Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
January 04, 2022 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may...
Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection
December 15, 2021 16:05 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that...